Switch to:
Also traded in: Argentina, Germany, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Equity to Asset 0.55
NVS's Equity to Asset is ranked lower than
61% of the 671 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. NVS: 0.55 )
Ranked among companies with meaningful Equity to Asset only.
NVS' s Equity to Asset Range Over the Past 10 Years
Min: 0.51  Med: 0.58 Max: 0.65
Current: 0.55
0.51
0.65
Interest Coverage 12.24
NVS's Interest Coverage is ranked lower than
69% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 94.32 vs. NVS: 12.24 )
Ranked among companies with meaningful Interest Coverage only.
NVS' s Interest Coverage Range Over the Past 10 Years
Min: 12.22  Med: 17.39 Max: 30.91
Current: 12.24
12.22
30.91
F-Score: 5
Z-Score: 2.55
M-Score: -2.65
WACC vs ROIC
7.21%
7.63%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 16.97
NVS's Operating margin (%) is ranked higher than
75% of the 724 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.44 vs. NVS: 16.97 )
Ranked among companies with meaningful Operating margin (%) only.
NVS' s Operating margin (%) Range Over the Past 10 Years
Min: 16.97  Med: 20.87 Max: 22.35
Current: 16.97
16.97
22.35
Net-margin (%) 13.55
NVS's Net-margin (%) is ranked higher than
76% of the 726 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.90 vs. NVS: 13.55 )
Ranked among companies with meaningful Net-margin (%) only.
NVS' s Net-margin (%) Range Over the Past 10 Years
Min: 13.55  Med: 19.02 Max: 31.38
Current: 13.55
13.55
31.38
ROE (%) 9.04
NVS's ROE (%) is ranked higher than
59% of the 753 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.76 vs. NVS: 9.04 )
Ranked among companies with meaningful ROE (%) only.
NVS' s ROE (%) Range Over the Past 10 Years
Min: 9.04  Med: 15.32 Max: 25.73
Current: 9.04
9.04
25.73
ROA (%) 5.13
NVS's ROA (%) is ranked higher than
60% of the 783 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.54 vs. NVS: 5.13 )
Ranked among companies with meaningful ROA (%) only.
NVS' s ROA (%) Range Over the Past 10 Years
Min: 5.13  Med: 8.97 Max: 16.18
Current: 5.13
5.13
16.18
ROC (Joel Greenblatt) (%) 44.71
NVS's ROC (Joel Greenblatt) (%) is ranked higher than
81% of the 776 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.07 vs. NVS: 44.71 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NVS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 43.77  Med: 62.42 Max: 77.56
Current: 44.71
43.77
77.56
Revenue Growth (3Y)(%) -2.10
NVS's Revenue Growth (3Y)(%) is ranked lower than
73% of the 604 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.60 vs. NVS: -2.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NVS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -2.8  Med: 4.8 Max: 73.5
Current: -2.1
-2.8
73.5
EBITDA Growth (3Y)(%) 5.40
NVS's EBITDA Growth (3Y)(%) is ranked lower than
58% of the 564 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.30 vs. NVS: 5.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NVS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -7.2  Med: 1.95 Max: 82.7
Current: 5.4
-7.2
82.7
EPS Growth (3Y)(%) 6.80
NVS's EPS Growth (3Y)(%) is ranked higher than
50% of the 529 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. NVS: 6.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NVS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -7.1  Med: 5.15 Max: 82
Current: 6.8
-7.1
82
» NVS's 10-Y Financials

Financials (Next Earnings Date: 2016-10-25)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

NVS Guru Trades in Q3 2015

Manning & Napier Advisors, Inc 2,780,106 sh (+116.13%)
Jim Simons 1,682,398 sh (+41.78%)
Sarah Ketterer 262,666 sh (+10.96%)
Murray Stahl 28,750 sh (+5.12%)
Kahn Brothers 28,543 sh (+1.42%)
Ken Fisher 6,132,211 sh (+1.28%)
First Eagle Investment 12,848 sh (unchged)
RS Investment Management 2,825 sh (unchged)
Mairs and Power 4,080 sh (unchged)
Pioneer Investments Sold Out
Tweedy Browne 249,022 sh (-2.04%)
Dodge & Cox 45,723,035 sh (-4.68%)
PRIMECAP Management 20,815,508 sh (-5.97%)
Mario Gabelli 7,540 sh (-9.48%)
John Hussman 50,000 sh (-50.00%)
» More
Q4 2015

NVS Guru Trades in Q4 2015

John Rogers 11,267 sh (New)
Jim Simons 3,091,198 sh (+83.74%)
Manning & Napier Advisors, Inc 3,507,436 sh (+26.16%)
Sarah Ketterer 281,710 sh (+7.25%)
Ken Fisher 6,188,893 sh (+0.92%)
First Eagle Investment 12,848 sh (unchged)
Murray Stahl 28,750 sh (unchged)
Mairs and Power 4,080 sh (unchged)
Samuel Isaly 895,000 sh (unchged)
John Hussman Sold Out
RS Investment Management Sold Out
PRIMECAP Management 20,768,108 sh (-0.23%)
Dodge & Cox 45,107,085 sh (-1.35%)
Mario Gabelli 7,390 sh (-1.99%)
Tweedy Browne 242,201 sh (-2.74%)
Kahn Brothers 27,643 sh (-3.15%)
» More
Q1 2016

NVS Guru Trades in Q1 2016

Tom Gayner 3,700 sh (New)
John Rogers 13,296 sh (+18.01%)
Sarah Ketterer 316,362 sh (+12.30%)
Jim Simons 3,264,498 sh (+5.61%)
Manning & Napier Advisors, Inc 3,638,373 sh (+3.73%)
Murray Stahl 29,250 sh (+1.74%)
Ken Fisher 6,287,099 sh (+1.59%)
PRIMECAP Management 20,938,858 sh (+0.82%)
Kahn Brothers 27,643 sh (unchged)
First Eagle Investment 12,848 sh (unchged)
Dodge & Cox 45,054,916 sh (-0.12%)
Tweedy Browne 237,664 sh (-1.87%)
Mario Gabelli 6,865 sh (-7.10%)
Mairs and Power 3,780 sh (-7.35%)
Samuel Isaly 457,700 sh (-48.86%)
» More
Q2 2016

NVS Guru Trades in Q2 2016

John Rogers 14,818 sh (+11.45%)
Ken Fisher 6,363,641 sh (+1.22%)
Sarah Ketterer 319,351 sh (+0.94%)
Tom Gayner 3,700 sh (unchged)
Murray Stahl 29,250 sh (unchged)
First Eagle Investment 12,848 sh (unchged)
Kahn Brothers 27,643 sh (unchged)
Mairs and Power 3,780 sh (unchged)
PRIMECAP Management 20,831,508 sh (-0.51%)
Dodge & Cox 44,366,511 sh (-1.53%)
Tweedy Browne 233,783 sh (-1.63%)
Manning & Napier Advisors, Inc 3,564,657 sh (-2.03%)
Mario Gabelli 6,015 sh (-12.38%)
Jim Simons 2,260,598 sh (-30.75%)
Samuel Isaly 255,700 sh (-44.13%)
» More
» Details

Insider Trades

Latest Guru Trades with NVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NYSE:PFE, NYSE:MRK, NYSE:ABBV, OTCPK:GLAXF, NYSE:SNY, NYSE:BMY, NYSE:LLY, NYSE:AZN, OTCPK:BAYRY, NYSE:JNJ, OTCPK:SZUKF, OTCPK:ALPMY, OTCPK:OTSKF, OTCPK:CHGCY, OTCPK:DSNKY, OTCPK:OPHLY, OTCPK:KYKOF, OTCPK:PTKFY, OTCPK:SNPHY, OTCPK:MAYNF » details
Traded in other countries:NVS.Argentina, NOT.Germany, NVS N.Mexico, NOVN.Switzerland, 0HKE.UK, NVSEF.USA,
Novartis AG is engaged in the research, development, manufacturing and marketing of healthcare products and pharmaceuticals.

Novartis AG was incorporated on February 29, 1996 under the Swiss laws. On December 20, 1996, its predecessor companies, Ciba-Geigy AG and Sandoz AG, merged into this new entity, creating Novartis. The Company is engaged in the research, development, manufacturing and marketing of healthcare and pharmaceuticals products. The Company's portfolio includesmedicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. The Company's wholly-owned businesses are organized into six global operating divisions, and report teir results in the following five segments; Pharmaceuticals: Innovative patent-protected prescription medicines, Alcon: Surgical, ophthalmic pharmaceutical and vision care products, Sandoz: Generic pharmaceuticals, Vaccines and Diagnostics: Preventive human vaccines and blood testing diagnostics, Consumer Health: OTC (over-the-counter medicines) and Animal Health. The Pharmaceuticals division researches, develops, manufactures, distributes and sells patented prescription medicines and is organized in the following business franchises: Primary Care, consisting of Primary Care medicines and Established Medicines; and Specialty Care, consisting of Ophthalmology, Neuroscience, Integrated Hospital Care, and Critical Care medicines. The manufacture of the products is complex and heavily regulated by governmental health authorities, which means that supply is never guaranteed. If the Company or its third party suppliers fail to comply with applicable regulations then there could be a product recall or other shutdown or disruption of its production activities. The Company is subject to the laws of Switzerland, in particular Swiss company and securities laws, and to the securities laws of the United States as applicable to foreign private issuers of securities.

Top Ranked Articles about Novartis AG

Does Biotech’s Recent Bounce Have Legs? Examining 3 Big Pharma stocks that dominate the making of cancer-fighting treatments
The beleaguered biotechology sector, which has endured political controversy amid charges of price gouging, is now on an upward trajectory. The Nasdaq Biotechnology Index, after falling 17.46% year to date, has jumped 9.04% over the past month. Read more...
Guru Stocks at 52-Week Lows: NVS, WMT, IBM, AXP, CHU Stocks that have recently reached their historical low prices
According to GuruFocus list of 52-week lows, these Guru stocks have reached their 52-week lows. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 27.87
NVS's P/E(ttm) is ranked higher than
50% of the 538 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.52 vs. NVS: 27.87 )
Ranked among companies with meaningful P/E(ttm) only.
NVS' s P/E(ttm) Range Over the Past 10 Years
Min: 5.7  Med: 15.96 Max: 29.97
Current: 27.87
5.7
29.97
Forward P/E 15.36
NVS's Forward P/E is ranked higher than
59% of the 69 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.76 vs. NVS: 15.36 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 28.31
NVS's PE(NRI) is ranked lower than
51% of the 537 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.50 vs. NVS: 28.31 )
Ranked among companies with meaningful PE(NRI) only.
NVS' s PE(NRI) Range Over the Past 10 Years
Min: 10.63  Med: 18.24 Max: 31.15
Current: 28.31
10.63
31.15
Price/Owner Earnings (ttm) 18.70
NVS's Price/Owner Earnings (ttm) is ranked higher than
75% of the 276 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.08 vs. NVS: 18.70 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
NVS' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 7.18  Med: 16.53 Max: 24.16
Current: 18.7
7.18
24.16
P/B 2.56
NVS's P/B is ranked higher than
57% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.08 vs. NVS: 2.56 )
Ranked among companies with meaningful P/B only.
NVS' s P/B Range Over the Past 10 Years
Min: 1.69  Med: 2.49 Max: 4.14
Current: 2.56
1.69
4.14
P/S 3.77
NVS's P/S is ranked lower than
60% of the 695 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.86 vs. NVS: 3.77 )
Ranked among companies with meaningful P/S only.
NVS' s P/S Range Over the Past 10 Years
Min: 1.89  Med: 3.1 Max: 5.01
Current: 3.77
1.89
5.01
PFCF 21.40
NVS's PFCF is ranked higher than
53% of the 193 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.56 vs. NVS: 21.40 )
Ranked among companies with meaningful PFCF only.
NVS' s PFCF Range Over the Past 10 Years
Min: 7.05  Med: 17.41 Max: 26.97
Current: 21.4
7.05
26.97
POCF 15.82
NVS's POCF is ranked higher than
51% of the 256 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.62 vs. NVS: 15.82 )
Ranked among companies with meaningful POCF only.
NVS' s POCF Range Over the Past 10 Years
Min: 5.77  Med: 13.26 Max: 19.3
Current: 15.82
5.77
19.3
EV-to-EBIT 25.23
NVS's EV-to-EBIT is ranked lower than
61% of the 529 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.31 vs. NVS: 25.23 )
Ranked among companies with meaningful EV-to-EBIT only.
NVS' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.5  Med: 15.5 Max: 27
Current: 25.23
8.5
27
EV-to-EBITDA 16.89
NVS's EV-to-EBITDA is ranked higher than
50% of the 557 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.21 vs. NVS: 16.89 )
Ranked among companies with meaningful EV-to-EBITDA only.
NVS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.3  Med: 11.9 Max: 18.1
Current: 16.89
7.3
18.1
Shiller P/E 15.71
NVS's Shiller P/E is ranked higher than
91% of the 159 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 49.59 vs. NVS: 15.71 )
Ranked among companies with meaningful Shiller P/E only.
NVS' s Shiller P/E Range Over the Past 10 Years
Min: 9.66  Med: 14.61 Max: 21.48
Current: 15.71
9.66
21.48
Current Ratio 0.90
NVS's Current Ratio is ranked lower than
90% of the 678 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.47 vs. NVS: 0.90 )
Ranked among companies with meaningful Current Ratio only.
NVS' s Current Ratio Range Over the Past 10 Years
Min: 0.83  Med: 1.39 Max: 2.83
Current: 0.9
0.83
2.83
Quick Ratio 0.65
NVS's Quick Ratio is ranked lower than
90% of the 678 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.81 vs. NVS: 0.65 )
Ranked among companies with meaningful Quick Ratio only.
NVS' s Quick Ratio Range Over the Past 10 Years
Min: 0.59  Med: 1.14 Max: 2.48
Current: 0.65
0.59
2.48
Days Inventory 134.29
NVS's Days Inventory is ranked lower than
60% of the 679 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 115.00 vs. NVS: 134.29 )
Ranked among companies with meaningful Days Inventory only.
NVS' s Days Inventory Range Over the Past 10 Years
Min: 117.85  Med: 159.97 Max: 183.42
Current: 134.29
117.85
183.42
Days Sales Outstanding 62.45
NVS's Days Sales Outstanding is ranked higher than
62% of the 579 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 77.08 vs. NVS: 62.45 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.31  Med: 63.74 Max: 69.89
Current: 62.45
56.31
69.89
Days Payable 100.98
NVS's Days Payable is ranked higher than
71% of the 526 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 67.81 vs. NVS: 100.98 )
Ranked among companies with meaningful Days Payable only.
NVS' s Days Payable Range Over the Past 10 Years
Min: 95.93  Med: 108.59 Max: 120.63
Current: 100.98
95.93
120.63

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.45
NVS's Dividend Yield is ranked higher than
90% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.52 vs. NVS: 3.45 )
Ranked among companies with meaningful Dividend Yield only.
NVS' s Dividend Yield Range Over the Past 10 Years
Min: 1.47  Med: 3.28 Max: 5.11
Current: 3.45
1.47
5.11
Dividend Payout 0.98
NVS's Dividend Payout is ranked higher than
68% of the 372 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.35 vs. NVS: 0.98 )
Ranked among companies with meaningful Dividend Payout only.
NVS' s Dividend Payout Range Over the Past 10 Years
Min: 0.98  Med: 1.67 Max: 3.22
Current: 0.98
0.98
3.22
Dividend Growth (3y) 6.80
NVS's Dividend Growth (3y) is ranked lower than
52% of the 290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. NVS: 6.80 )
Ranked among companies with meaningful Dividend Growth (3y) only.
NVS' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 7.45 Max: 18.5
Current: 6.8
0
18.5
Forward Dividend Yield 3.43
NVS's Forward Dividend Yield is ranked higher than
82% of the 579 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.51 vs. NVS: 3.43 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 5.02
NVS's Yield on cost (5-Year) is ranked higher than
91% of the 717 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.04 vs. NVS: 5.02 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
NVS' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.14  Med: 4.77 Max: 7.44
Current: 5.02
2.14
7.44
3-Year Average Share Buyback Ratio 0.10
NVS's 3-Year Average Share Buyback Ratio is ranked higher than
85% of the 432 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.80 vs. NVS: 0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -166.2  Med: -0.15 Max: 2.3
Current: 0.1
-166.2
2.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 24.45
NVS's Price/Tangible Book is ranked lower than
96% of the 645 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.80 vs. NVS: 24.45 )
Ranked among companies with meaningful Price/Tangible Book only.
NVS' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.32  Med: 4.27 Max: 12455
Current: 24.45
0.32
12455
Price/Projected FCF 1.25
NVS's Price/Projected FCF is ranked higher than
79% of the 287 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.65 vs. NVS: 1.25 )
Ranked among companies with meaningful Price/Projected FCF only.
NVS' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.66  Med: 1.13 Max: 5.43
Current: 1.25
0.66
5.43
Price/Median PS Value 1.22
NVS's Price/Median PS Value is ranked lower than
58% of the 637 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.16 vs. NVS: 1.22 )
Ranked among companies with meaningful Price/Median PS Value only.
NVS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.68  Med: 1.18 Max: 3.27
Current: 1.22
0.68
3.27
Price/Graham Number 5.54
NVS's Price/Graham Number is ranked lower than
86% of the 400 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. NVS: 5.54 )
Ranked among companies with meaningful Price/Graham Number only.
NVS' s Price/Graham Number Range Over the Past 10 Years
Min: 0.61  Med: 1.97 Max: 81.67
Current: 5.54
0.61
81.67
Earnings Yield (Greenblatt) (%) 4.05
NVS's Earnings Yield (Greenblatt) (%) is ranked higher than
58% of the 752 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. NVS: 4.05 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NVS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.7  Med: 6.45 Max: 11.8
Current: 4.05
3.7
11.8
Forward Rate of Return (Yacktman) (%) 3.31
NVS's Forward Rate of Return (Yacktman) (%) is ranked lower than
58% of the 330 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.64 vs. NVS: 3.31 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
NVS' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1.8  Med: 14.1 Max: 69.5
Current: 3.31
1.8
69.5

More Statistics

Revenue (TTM) (Mil) $49,778
EPS (TTM) $ 2.81
Beta0.69
Short Percentage of Float0.15%
52-Week Range $69.90 - 95.11
Shares Outstanding (Mil)2,381.20

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 49,672 50,338 53,885
EPS ($) 4.77 5.12 5.84
EPS w/o NRI ($) 4.77 5.12 5.84
EPS Growth Rate
(3Y to 5Y Estimate)
3.75%
Dividends Per Share ($) 2.79 2.90 3.13
» More Articles for NVS

Headlines

Articles On GuruFocus.com
A Double Dose of Trouble at Novartis Sep 22 2016 
Merck Will Hold Steady on Div Increase Despite Flat Revenue Growth Aug 31 2016 
Can Novartis Tide Over the Alcon Crisis? Aug 26 2016 
Pharmaceuticals are the New Bonds Aug 30 2016 
Merck Offers Value and Steady Dividend Growth Aug 24 2016 
Novartis: First-Class Pharmaceuticals Aug 19 2016 
Novartis Needs to Stem the Bleeding From Gleevec Decline Aug 16 2016 
GlaxoSmithKline's Dividend Health Aug 09 2016 
Can Novartis Win the Entresto Bet? Aug 03 2016 
Tweedy Browne 2nd Quarter Shareholder Letter Aug 01 2016 

More From Other Websites
Prothena Builds On Psoriasis Science For Arthritis Treatment Sep 30 2016
SQZ Biotech nabs $16M funding, hires former Novartis exec Sep 30 2016
Amgen Migraine Drug Likely To Beat Eli Lilly, Alder, Teva To Market Sep 29 2016
7 Healthcare Stocks in Focus on World Heart Day Sep 29 2016
5 Big Breakout Trades You Should Have in Your Portfolio This Fall Sep 29 2016
Novartis announces Phase III study shows AMG 334 significantly reduces monthly migraine days in... Sep 28 2016
Kite Pharma Soars As Cancer Drug Trial Supportive Of FDA Approval Sep 27 2016
Juno Therapeutics Viewed As A Sympathy Play On Kite Pharma's KTE-C19 Sep 27 2016
ETF’s with exposure to Novartis AG : September 26, 2016 Sep 26 2016
The Internet of Medical Things: 6 Stocks in Focus Sep 26 2016
Novartis Ilaris Approved for Extended Use in Periodic Fever Sep 26 2016
Novartis receives three new FDA approvals for the expanded use of Ilaris for patients with rare... Sep 23 2016
Novartis receives three new FDA approvals for the expanded use of Ilaris treating rare Periodic... Sep 23 2016
Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study Sep 23 2016
UPDATE 1-Novartis's Zykadia gets positive results, faces Roche pressure Sep 23 2016
Novartis announces positive top-line results from ASCEND-4, a Phase III trial of Zykadia® in... Sep 23 2016
Gilead, Allergan Seen Trailing Intercept In Ongoing NASH Battle Sep 22 2016
A Double Dose of Trouble at Novartis Sep 22 2016
Does Novartis AG (NVS) Have The Solution For Malaria? Sep 22 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)